In an open-label Phase 2 study of adults with Stage 3 type 1 diabetes, 12 weeks of the menin inhibitor icovamenib 200 mg produced a 52% increase from baseline in mean stimulated C‑peptide AUC at Week 12 (p<0.001; n=5) among patients diagnosed within 0–3 years, with a dose response versus 100 mg (n=6). After stopping therapy, mean C‑peptide in the 200 mg cohort was largely preserved through Week 52, showing an approximately 7% decline from baseline. In patients diagnosed 3–15 years prior (n=9), C‑peptide was generally preserved through Week 52. Across arms, icovamenib was reported as generally well tolerated with no new safety signals over 52 weeks. The core development is Biomea Fusion’s 52‑week readout from COVALENT‑112, a proof‑of‑concept trial that tested short‑course icovamenib in two duration‑of‑disease cohorts and signaled functional beta‑cell effects beyond the dosing window. The program’s cadence was disrupted by an FDA clinical hold in 2024 that halted enrollment and prevented completion of a planned placebo‑controlled Part 2; the hold has since been resolved, leaving roughly half the intended sample size. The company plans a new Phase 2 study in patients within three years of diagnosis, extending dosing to 6 or 12 months at 200 mg and adding an arm with an immunosuppressive agent. A fuller dataset is slated for presentation at the ADA Scientific Sessions in June. Strategically, this moves Biomea into the narrow gap between immune‑modulating preservation strategies and cell‑replacement approaches by attempting to regenerate or restore beta‑cell function with a time‑limited, oral therapy. The dose response and durability signal, if reproducible, would support a beta‑cell–centric mechanism distinct from chronic immunosuppression and may allow for simpler long‑term management. The addition of an immunosuppressive arm acknowledges ongoing autoimmune pressure in Stage 3 T1D and hedges toward combination strategies if monotherapy durability wanes with longer follow‑up. However, the small, uncontrolled dataset heightens the risk that natural history variability, assay noise in MMTT‑derived C‑peptide, and selection effects are inflating the signal. The prior clinical hold introduces a parallel regulatory narrative that will require clean safety and class‑specific risk management. [adrotate group="1"] For sites and CROs, a short‑course oral regimen lowers procedural intensity relative to infusion‑based immunotherapies, but operational complexity remains: standardized MMTT, central lab harmonization, CGM data capture, insulin titration documentation, and longer off‑drug follow‑up to assess persistence. If the next study includes immunosuppression, monitoring burden, AE management, and exclusion criteria will expand, affecting throughput and retention. Sponsors and payers will look for convergent evidence beyond C‑peptide—reductions in exogenous insulin, maintenance or improvement of HbA1c and time‑in‑range without excess hypoglycemia—to translate biomarker effects into clinical utility. Regulators have historically accepted C‑peptide as a preservation marker in early T1D; for established Stage 3 disease, durability off therapy and functional outcomes will likely determine whether C‑peptide can anchor a registrational strategy. Near term, the ADA presentation needs to clarify individual patient trajectories, variance, assay methods, insulin dose changes, CGM metrics, and comprehensive safety. The forthcoming Phase 2 design will signal regulatory intent: randomization, placebo control, stratification by disease duration and baseline C‑peptide, and predefined durability windows are critical. Key risks include attenuation of effect with a larger, controlled sample, safety trade‑offs if combined with immunosuppression, and the challenge of demonstrating clinically meaningful benefit that persists after stopping therapy. Watch for alignment with FDA on endpoints and follow‑up duration, biomarker‑based enrichment strategies, and site selection capable of high‑fidelity MMTT and CGM workflows, which will determine whether this early signal can mature into a scalable, disease‑modifying pathway for Stage 3 T1D. [adrotate group="1"] Source link: https://www.globenewswire.com/news-release/2026/04/27/3282109/0/en/Biomea-Fusion-Announces-Positive-52-Week-Results-from-Phase-2-COVALENT-112-Trial-in-Type-1-Diabetes-Showing-C-Peptide-Improvement-and-Durability-Following-12-Weeks-of-Icovamenib-Tr.html
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
